Synchronization of Administrations of Chemotherapy and Erythropoiesis-stimulating Agents and Frequency of Associated Healthcare Visits

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2013 Jun 13

PMID 23756616

Authors

Jerrold W Hill

Sanatan Shreay

November McGarvey

Ajita P De

Gregory P Hess

Patricia K Corey-Lisle

Affiliations

Soon will be listed here.

Abstract

Purpose: The erythropoiesis-stimulating agents (ESAs), darbepoetin alfa (DA), and epoetin alfa (EA) differ with respect to dosing schedule in chemotherapy-induced anemia. DA can be administered less frequently than EA, which may increase synchronicity between chemotherapy and ESA schedules. This study compared DA and EA with respect to frequency of synchronization and frequencies of total and ESA healthcare visits in current clinical practice.

Methods: A retrospective analysis of ESA utilization during ESA episodes of care was conducted on all cancer patients identified in the SDI health oncology electronic medical records database who underwent chemotherapy and received ESA therapy from July 1, 2007 to March 31, 2010 (n = 6522 DA, n = 3,439 EA).

Results: The frequency of synchronization (chemotherapy and ESA therapy on the same day) was higher with DA (67 %) than EA (58 %) (p < 0.001). The odds that an ESA administration was synchronized with chemotherapy were higher with DA compared with EA (odds ratio = 1.46, 95 % CI: 1.37, 1.54). Compared with EA, DA patients had 2.3 fewer visits with an ESA administration (p < 0.001) and 3.0 fewer total visits (p < 0.001).

Conclusions: Compared with patients receiving EA, DA patients were more likely to have an ESA administration on the same healthcare visit as chemotherapy and had fewer visits for any cause or for ESA administration. These results suggest that through greater synchronization of ESA and chemotherapy administrations, DA may reduce patient and practice burden and healthcare utilization.

References

Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A . The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia. Pharmacoeconomics. 2009; 27(9):755-65. DOI: 10.2165/11313860-000000000-00000. View

Calabrich A, Katz A . Management of anemia in cancer patients. Future Oncol. 2011; 7(4):507-17. DOI: 10.2217/fon.11.24. View

Knight K, Wade S, Balducci L . Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:11S-26S. DOI: 10.1016/j.amjmed.2003.12.008. View

Muller R, Baribeault D . Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. Am J Health Syst Pharm. 2007; 64(24):2547-56. DOI: 10.2146/ajhp070018. View

Tunceli O, Bailey R, Stephenson J, Singer J . Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy. J Oncol Pharm Pract. 2012; 19(4):305-14. DOI: 10.1177/1078155212466123. View

Pronzato P, Cortesi E, van der Rijt C, Bols A, Moreno-Nogueira J, de Oliveira C . Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist. 2010; 15(9):935-43. PMC: 3228044. DOI: 10.1634/theoncologist.2009-0279. View

Berger A, Lord C, Corey-Lisle P, Williams G, Oster G . Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy. Clin Ther. 2012; 34(6):1350-63. DOI: 10.1016/j.clinthera.2012.04.020. View

Ross S, Allen I, Henry D, Seaman C, Sercus B, Goodnough L . Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006; 28(6):801-31. DOI: 10.1016/j.clinthera.2006.06.003. View

Boccia R, Malik I, Raja V, Kahanic S, Liu R, Lillie T . Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist. 2006; 11(4):409-17. DOI: 10.1634/theoncologist.11-4-409. View

10.

Hess G, Nordyke R, Hill J, Hulnick S . Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol. 2010; 85(11):838-43. DOI: 10.1002/ajh.21837. View

11.

Cersosimo R, Jacobson D . Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother. 2005; 40(1):58-65. DOI: 10.1345/aph.1G042. View

12.

Stull D, Vernon M, Legg J, Viswanathan H, Fairclough D, Revicki D . Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue. Contemp Clin Trials. 2010; 31(2):172-9. DOI: 10.1016/j.cct.2009.12.006. View

13.

Puglisi F, Deroma L, Russo S, Carteni G, Sporchia A, Ucci G . Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol. 2008; 69(2):175-82. DOI: 10.1016/j.critrevonc.2008.07.010. View

14.

Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N . Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol. 2009; 39(3):163-8. DOI: 10.1093/jjco/hyn151. View

15.

Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K . Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. Jpn J Clin Oncol. 2010; 40(6):521-9. DOI: 10.1093/jjco/hyq017. View

16.

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T . Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin. 2009; 25(9):2109-20. DOI: 10.1185/03007990903084164. View